Akero
Patrick Lamy is Senior Vice President of Commercial Strategy at Akero. He brings over 25 years of experience in building commercial teams, leading global product launches, and developing strategic plans to ensure the success of both large and small pharmaceutical companies. Prior to joining Akero, he held various commercial planning and strategy, and alliance management roles at Iovance Biotherapeutics and Gilead Sciences. Patrick studied biochemistry and cellular biology at the University of California, San Diego, and received his M.B.A. from the University of California Berkeley.
This person is not in any teams
This person is not in any offices
Akero
1 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.